Elanco Animal Health Incorporated (ELAN) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | (m) | |
| Revenue | 5.02B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 2.24B USD | Cost of Goods and Services Sold |
| Research and development | 371.00M USD | Research and Development Expense |
| Selling, general and administration | 1.52B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.02B | $2.24B | $371.00M | $1.52B | (m) |
| 2026-03-31 | (m) | $4.89B | $2.20B | $371.00M | $1.47B | (m) |
| 2025-12-31 | (m) | $4.71B | $2.12B | $368.00M | $1.43B | (m) |
| 2025-09-30 | (m) | $4.59B | $2.07B | $356.00M | $1.39B | (m) |
| 2025-06-30 | (m) | $4.48B | $2.03B | $354.00M | $1.36B | (m) |
| 2025-03-31 | (m) | $4.43B | $2.00B | $351.00M | $1.32B | (m) |
| 2024-12-31 | (m) | $4.44B | $2.00B | $344.00M | $1.31B | (m) |
| 2024-09-30 | (m) | $4.45B | $2.02B | $342.00M | $1.31B | (m) |
| 2024-06-30 | (m) | $4.49B | $2.01B | $341.00M | $1.30B | (m) |
| 2024-03-31 | (m) | $4.37B | $1.95B | $333.00M | $1.29B | (m) |
| 2023-12-31 | (m) | $4.42B | $1.93B | $327.00M | $1.28B | (m) |
| 2023-09-30 | (m) | $4.37B | $1.86B | $328.00M | $1.29B | (m) |
| 2023-06-30 | (m) | $4.32B | $1.85B | $320.00M | $1.28B | (m) |
| 2023-03-31 | (m) | $4.44B | $1.90B | $321.00M | $1.27B | (m) |
| 2022-12-31 | (m) | $4.41B | $1.91B | $321.00M | $1.26B | (m) |
| 2022-09-30 | (m) | $4.54B | $1.98B | $333.00M | $1.29B | (m) |
| 2022-06-30 | (m) | $4.65B | $2.01B | $349.00M | $1.33B | (m) |
| 2022-03-31 | (m) | $4.75B | $2.07B | $361.00M | $1.38B | (m) |
| 2021-12-31 | (m) | $4.76B | $2.13B | $369.00M | $1.40B | (m) |
| 2021-09-30 | (m) | $4.79B | $2.22B | $390.00M | $1.45B | (m) |
| 2021-06-30 | (m) | $4.55B | $2.16B | $384.00M | $1.38B | (m) |
| 2021-03-31 | (m) | $3.86B | $1.90B | $349.00M | $1.16B | (m) |
| 2020-12-31 | (m) | $3.27B | $1.67B | $327.00M | $996.60M | (m) |
| 2020-09-30 | (m) | $2.92B | $1.48B | $281.60M | $808.40M | (m) |
| 2020-06-30 | (m) | $2.80B | $1.40B | $263.40M | $723.00M | (m) |
| 2020-03-31 | (m) | $3.00B | $1.46B | $272.80M | $761.10M | (m) |
| 2019-12-31 | (m) | $3.07B | $1.47B | $270.10M | $760.20M | (m) |
| 2019-09-30 | (m) | $3.08B | $1.47B | $263.90M | $759.40M | (m) |
| 2019-06-30 | (m) | $3.07B | $1.48B | $252.90M | $746.10M | (m) |
| 2019-03-31 | (m) | $3.06B | $1.56B | $245.50M | $736.30M | (m) |
| 2018-12-31 | (m) | $3.07B | $1.57B | $246.60M | $735.20M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $1.57B | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $1.52B | (m) | (m) | (m) |
| 2017-12-31 | (m) | $2.89B | $1.49B | $251.70M | $779.80M | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.91B | $1.41B | $265.80M | $784.80M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |